Who is it for?
People seeking a second medical opinion, Japan oncology consultation, or evaluation of cell-based immunotherapy as a possible discussion topic within comprehensive care.
Japan's latest generation NK cell and dendritic cell immunotherapy activates and enhances the body's own immune system to precisely identify and eliminate cancer cells — 6–10 billion highly active immune cells per infusion.
Book Expert Assessment →Immunotherapy differs from surgery, chemotherapy, and radiation — rather than attacking tumors from outside, it activates and enhances the immune defense system already within your body, making NK cells and T cells the most precise "hunters" against cancer.
Japanese scientist Tasuku Honjo won the Nobel Prize for immune checkpoint inhibitor research, confirming Japan's global leadership in cancer immunotherapy. By activating patients' own immune cells and vastly amplifying their quantity and activity before reinfusion, a multi-level cancer defense barrier is established.
This therapy can be used synergistically with surgery, chemotherapy, and radiation — enhancing overall treatment efficacy while reducing side effects of conventional treatments, helping patients maintain a better quality of life.
Rejuvenated NK Cell Technology · Mitochondrial Activation · Dual-Cell Synergy · High-Dose Precision Infusion · Aerospace-grade Sterile Production · Multiple Government Certifications — six-dimensional technology for the strongest immune defense.
Precisely matched immune treatment plans for different needs and stages
NK (Natural Killer) cells are the body's innate cancer fighters — attacking tumors directly without needing specific antigen recognition. Rejuvenation culture technology restores NK cell activity to youthful levels, dramatically boosting killing efficiency.
Dendritic cells are the "commanders" of the immune system, identifying tumor-specific antigens and activating T cells for precision strikes. Dendritic cell vaccine therapy trains the immune system to develop lasting, targeted memory against specific cancers.
Combining NK cells' broad-spectrum killing with dendritic cells' precision targeting builds a multi-level, three-dimensional immune defense network. This synergy doubles treatment efficacy — Japan's most advanced combination immunotherapy.
Every technical innovation stems from the ultimate responsibility toward patient lives
A unique culture process restores age-degraded NK cell function to a youthful state, increasing killing activity several-fold and breaking through the age-related limitations on immunotherapy effectiveness.
Mitochondrial activation technology provides sustained energy for immune cells, allowing NK cells to maintain high-activity combat status in the body for longer — significantly improving treatment durability.
NK cells handle broad-spectrum immediate killing; dendritic cells provide precision targeted activation. The two cell types coordinate to cover multiple tumor escape mechanisms for more comprehensive defense.
Each treatment infuses 6–10 billion highly active cells — far exceeding standard treatment levels. Precise dose management ensures sufficient cells reach the lesion site for maximum therapeutic effect.
Cell collection, culture, expansion, and infusion are all performed in Class 100 sterile cleanrooms — infection control equivalent to spacecraft component manufacturing, eliminating all production-stage safety risks.
All partner institutions hold multiple MHLW and PMDA approvals — Japan's government's highest-level endorsement of the safety and efficacy of this therapy.
From disease assessment to ongoing monitoring — JMedPass's expert Chinese support
Comprehensive disease and immune status evaluation to confirm suitable treatment plan
Japan oncology immunologist designs personalized treatment plan and schedule
Autologous immune cells collected and cultured in aerospace-grade sterile laboratory
High-activity immune cells infused to activate multi-level immune defense system
Regular immune indicators and treatment efficacy assessment, dynamic plan adjustment
From cancer patients to high-risk groups, immune cell therapy provides multi-level protection
Combined with surgery/chemotherapy/radiotherapy — enhances overall treatment, reduces side effects, improves quality of life
Family cancer history or high-risk genetic testing — wants to proactively strengthen immunity for prevention
After cancer treatment, concerned about recurrence — building a long-term anti-cancer defense line
Frequent infections, chronic fatigue, sub-health state — seeking systematic immune function improvement
Scientific understanding for rational cancer management
Cancer-related immunotherapy decisions must consider pathology, staging, prior treatment, performance status and oncologist advice.
People seeking a second medical opinion, Japan oncology consultation, or evaluation of cell-based immunotherapy as a possible discussion topic within comprehensive care.
Medical record translation, imaging and pathology review, specialist consultation, treatment boundary explanation, cost confirmation, travel or remote follow-up coordination.
Costs vary by cell type, treatment frequency and institution. Any page-level price is only a reference; final quotation should come from the medical institution.
Cell-based immunotherapy must not replace standard treatment recommended by doctors. Combination with surgery, chemotherapy, radiotherapy, targeted therapy or immuno-oncology drugs requires oncologist guidance.
Eligibility for NK cells, dendritic cells or other programs depends on cancer type, stage, treatment history, immune markers and physician review.
Pathology report, staging, genetic test results, CT/MRI/PET-CT images and reports, prior treatment history, recent blood tests and treating doctor notes.
JMedPass does not promise tumor shrinkage, cure or survival benefit. Treatment choices require oncology specialist assessment.